GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aura Biosciences Inc (NAS:AURA) » Definitions » Total Current Liabilities

Aura Biosciences (Aura Biosciences) Total Current Liabilities : $9.66 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aura Biosciences Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Aura Biosciences's total current liabilities for the quarter that ended in Mar. 2024 was $9.66

Aura Biosciences Total Current Liabilities Historical Data

The historical data trend for Aura Biosciences's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aura Biosciences Total Current Liabilities Chart

Aura Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
6.15 2.66 7.36 10.46 12.36

Aura Biosciences Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.11 8.90 10.89 12.36 9.66

Aura Biosciences Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Aura Biosciences's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=5.232+2.687
+Other Current Liabilities+Current Deferred Liabilities
=4.438+0
=12.36

Aura Biosciences's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=4.442+2.741
+Other Current Liabilities+Current Deferred Liabilities
=2.48+0
=9.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Aura Biosciences Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Aura Biosciences's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aura Biosciences (Aura Biosciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aura Biosciences Inc (NAS:AURA) » Definitions » Total Current Liabilities
Comparable Companies
ERAS CHRS SPRY URGN OCS ITOS LXRX MGNX ORIC ICVX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
85 Bolton Street, Cambridge, MA, USA, 02140
Website
https://www.aurabiosciences.com
Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long-lasting anti-tumor immunity.
Executives
Matrix Capital Management Company, Lp 10 percent owner 1000 WINTER STREET, C/O MATRIX CAPITAL MANAGEMENT, WALTHAM MA 02451
David Michael Johnson director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Julie B Feder officer: Chief Financial Officer C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
De Los Pinos Elisabet director, officer: Chief Executive Officer C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Janet Jill Hopkins officer: See Remarks C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON MA 01235
Cadmus Rich officer: See Remarks C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Rosch Mark De officer: Chief Operating Officer C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Ventures Management (jersey) Ltd 10 percent owner C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth I Lp 10 percent owner C/O ELIAN FUND SERVICES (JERSEY) LIMITED, 44 ESPLANADE, ST HELIER Y9 JE4 9WG
Giovanni Mariggi director C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Growth I Gp Ltd 10 percent owner C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth Co-invest I Lp 10 percent owner C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
David E. Goel 10 percent owner C/O MATRIX CAPITAL MANAGEMENT CO., LP, 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Karan S. Takhar director C/O ZENTALIS PHARMACEUTICALS,INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Antony C. Mattessich director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730

Aura Biosciences (Aura Biosciences) Headlines

From GuruFocus

Aura Biosciences to Participate in Upcoming Investor Conferences

By Business Wire Business Wire • 05-24-2023

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

By Business Wire Business Wire • 02-16-2023

Aura Biosciences Presents Preclinical Data Highlighting AU-011's Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

By Business Wire Business Wire • 05-03-2022

Aura Biosciences to Participate in Upcoming Investor Conferences

By Business Wire Business Wire • 05-25-2022

Aura Biosciences to Participate in Upcoming Investor Conferences

By Business Wire Business Wire • 11-03-2022

Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

By Business Wire Business Wire • 05-26-2022

Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22

By Business Wire Business Wire • 03-15-2022

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

By Business Wire • 08-09-2023

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

By Business Wire Business Wire • 06-30-2022

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

By Business Wire Business Wire • 06-22-2022